Are the current guidelines for identification of myelodysplastic syndrome with germline predisposition strong enough? BRIT J HAEMATOL
Time trends and survival of marginal zone lymphoma over 25 years in Girona, Spain (1994-2018) CANCER MED-US
MYC activation impairs cell-intrinsic IFNy signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer Cell Rep Med
Feasibility of a New Model of Care for Allogeneic Stem Cell Transplantation Recipients Facilitated by eHealth: The MY-Medula Pilot Study TRANSPL CELL THER
Definition and Clinical Significance of the Monoclonal Gammopathy of Undetermined Significance-Like Phenotype in Patients With Monoclonal Gammopathies J Clin Oncol
Methodological and conceptual challenges to the flow cytometric classification of leukemic lymphoproliferative disorders CRIT REV CL LAB SCI
MSIMEP: Predicting microsatellite instability from microarray DNA methylation tumor profiles iScience
T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo PHARMACEUTICS
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes J Clin Oncol